ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2423

Concordance Between the 1990 ACR Classification Criteria and the New 2022 ACR/EULAR 2022 Criteria in Giant Cell Arteritis

Julio Sanchez Martin1, Julia Medina Valle1, Javier Loricera1, Maria Fe Garcia Reija1 and Ricardo Blanco2, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

Meeting: ACR Convergence 2023

Keywords: classification criteria, giant cell arteritis, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2387–2424) Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Classification criteria for vasculitis, including giant cell arteritis (GCA) are under constant revision. In 2022, the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria were presented, renewing those published by ACR in 1990. They include wider range of clinical criteria and imaging tests, such as ultrasonography (US) and Positron emission tomography (PET), which has contributed to the diagnosis of a higher number of cases.

The objective of this study was to assess the concordance between recent 2022 ACR/EULAR giant cell arteritis classification criteria and the criteria of ACR 1990 (1,2).

Methods: Observational study of patients diagnosed with GCA who underwent temporal artery biopsy (TAB) between 2016 and 2022 in an university hospital. Concordance between both sets of criteria were analyzed with Cohen’s kappa index.

Results: We present 191 patients (120 female/71 male) (mean±SD; 75±10 years). The main characteristics of the patients are shown in Table. The Kappa index between both criteria weighted by prevalence and bias was 0.654 (moderate-high degree of agreement). Global agreement of 83% was observed, with a higher specific agreement for negative results (88%) than for positive results (67%). Disagreement was observed in 16% of patients who were considered negative for ACR 1990 criteria but positive for ACR/EULAR 2022 criteria and in 2% who were considered positive for ACR 1990 criteria but negative for ACR/EULAR 2022. 2022 ACR/EULAR showed a higher sensitivity, and 27 additional patients were classified as GCA with these classification criteria.

Conclusion: Moderate-high concordance was found between 2022 ACR/EULAR and 1990 ACR classification criteria. However, the 2022 ACR/EULAR criteria consider a wider range of factors than the 1990 ACR criteria by introducing US and PET findings, thus increasing sensitivity and allowing a larger number of patients to be diagnosed. Cranial GCA was the most frequent phenotype observed.

References:
Ponte C, et al. Arthritis Rheumatol. 2022. PMID: 36350123
Hunder GG, et al. Arthritis Rheum. 1990. PMID: 2202311

Supporting image 1

Supporting image 2


Disclosures: J. Sanchez Martin: None; J. Medina Valle: None; J. Loricera: None; M. Garcia Reija: None; R. Blanco: AbbVie, 5, 6, Amgen, 6, AstraZeneca, 2, BMS, 6, Eli Lilly, 6, Galapagos, 2, 6, Janssen, 2, 6, MSD, 6, Novartis, 2, 6, Pfizer, 2, 6, Roche, 5, 6, Sanofi, 6.

To cite this abstract in AMA style:

Sanchez Martin J, Medina Valle J, Loricera J, Garcia Reija M, Blanco R. Concordance Between the 1990 ACR Classification Criteria and the New 2022 ACR/EULAR 2022 Criteria in Giant Cell Arteritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/concordance-between-the-1990-acr-classification-criteria-and-the-new-2022-acr-eular-2022-criteria-in-giant-cell-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/concordance-between-the-1990-acr-classification-criteria-and-the-new-2022-acr-eular-2022-criteria-in-giant-cell-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology